AZ Lynparza Head Hopes 2020 Will See PARP Inhibitor Treating Pancreatic Cancer

 
• By Sten Stovall

AstraZeneca and Merck & Co hope Lynparza will soon have a third treatment indication after their PARP inhibitor became the first to demonstrate a benefit in germline BRCA-mutated metastatic pancreatic cancer, having hit targets in the Phase III POLO trial.

Pancreas
Lynparza Phase III POLO Trial Met Primary PFS Endpoint In Pancreatic Cancer • Source: Shutterstock

More from Clinical Trials

More from R&D